Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma

The combination of targeted therapy with BRAF and MEK inhibitors has become the standard of care in patients with BRAF(V600E) mutant melanoma, but responses are not durable. In addition, the impressive clinical benefits with anti-PD-1 and anti-PD-L1 antibodies (Ab) in patients with heavily pretreate...

Descripción completa

Detalles Bibliográficos
Autores principales: Homet Moreno, Blanca, Mok, Stephen, Comin-Anduix, Begonya, Hu-Lieskovan, Siwen, Ribas, Antoni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006894/
https://www.ncbi.nlm.nih.gov/pubmed/27622011
http://dx.doi.org/10.1080/2162402X.2015.1052212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006894/
https://www.ncbi.nlm.nih.gov/pubmed/27622011
http://dx.doi.org/10.1080/2162402X.2015.1052212

Ejemplares similares